Whitepaper: Impact of the Claristep® Filtration System on recovery and adsorption of various therapeutic proteins at low sample volumes
Comparison of the Sartorius Claristep Filtration System with standard sample preparation using syringe filters.
We tested the novel filter device Claristep® for the preparation of protein samples containing one of four different target molecules: an anti-malaria vaccine candidate, aviscuminum, interferon alfa-2B or monoclonal antibody (mAb) P2G12. In comparison to the standard protocols for sample preparation prior to analysis by either reversed-phase or SEC HPLC, the Claristep® filter did not exhibit a significant difference in protein concentration if the target molecules were present with at least 1.0g L-1. A significantly reduced product concentration was observed in the Claristep® filtered samples compared to the standard protocol for mAb P2G12 if the concentrations were lower. The protein adsorption to the filter material was well described by a Langmuir adsorption isotherm. In addition, the Claristep® filters facilitated a rapid sample preparation with minimal volume losses.
Related content from this organisation
- Sartorius closes acquisition of selected assets of Danaher Life Sciences
- Active air sampler market to value $130.7 million by 2026
- Low costs of dispersible products to drive single-use bioprocessing market
- Intellectual property, divestments, fragmentation and the future: M&A in life sciences
- Viral vectors for gene therapy